EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health‐related quality of life and productivity

Koo Wilson, Carly Rich, Zalmai Hakimi, Regina Horneff, Jesse Fishman, Jennifer Mellor, Lucy Earl, Yasmin Taylor, Alice Simons, Joe Conyers, Brian Mulherin, Elaine Majerus und 1 weitere

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14139 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Koo Wilson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Sobi, Stockholm, Sweden. Hauptthemen laut MEDLINE: Quality of Life, Hemoglobinuria, Paroxysmal, Peptides, Cyclic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Apellis Pharmaceuticals, Swedish Orphan Biovitrum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To describe real‐world use/effectiveness of pegcetacoplan (PEG) in paroxysmal nocturnal haemoglobinuria (PNH).

Methods

Data were drawn from the Adelphi PNH Disease Specific Programme™, a cross‐sectional survey conducted in France, Italy, Germany, Spain and the United States from January to November 2022. Patients had a confirmed PNH diagnosis and received PEG for ≥1 month. Physicians reported patient characteristics, treatment use/satisfaction and their perception of patients' fatigue and health‐related quality of life (HRQoL). Patients reported treatment satisfaction and completed questionnaires assessing fatigue, HRQoL and productivity. Descriptive statistics were reported.

Results

Overall, 14 physicians provided data for 61 patients who had received 1080 mg/dose PEG for 1.3–14.8 months. At data collection compared to PEG initiation: haemoglobin was 2.5 g/dL higher on average; proportion of patients with lactate dehydrogenase (LDH) ≥1.5 × upper limit of normal was reduced by 27.4%; physician‐perceived fatigue was lower and HRQoL better. Physician‐ and patient‐reported treatment satisfaction was high for >90% of patients. Physicians and patients were more satisfied with PEG than previously prescribed C5 complement inhibitors. Mean work impairment and activity impairment in the 7 days prior to data collection were 32.9% and 22.4%, respectively.

Conclusions

These real‐world data support the effectiveness of PEG through positive effects on haemoglobin, LDH, fatigue and HRQoL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeHemoglobinuria, ParoxysmalPeptides, CyclicHumansUnited StatesCross-Sectional StudiesTreatment OutcomeL-Lactate DehydrogenaseHemoglobins

Stichwörter der Autor:innen

absenteeismcomplement inactivating agentsparoxysmal nocturnal haemoglobinuriapegcetacoplanpresenteeismquality of liferare diseasesreal-world evidence

Substanzen

pegcetacoplanL-Lactate DehydrogenaseHemoglobinsPeptides, Cyclic

Autor:innen und Institutionen

  • Sobi, Stockholm, Sweden.
  • Apellis Pharmaceuticals, Waltham, Massachusetts, USA.
  • Adelphi Real World, Cheshire, UK.
  • Hematology Oncology of Indiana, Indianapolis, Indiana, USA.
  • Department of Medicine, Washington University, St. Louis, Missouri, USA.
  • Department of Hematology and Stem Cell Transplantation, University Hospital Essen, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.

Förderung

  • Apellis Pharmaceuticals
  • Swedish Orphan Biovitrum

Zitieren

APA

Wilson, K., Rich, C., Hakimi, Z., Horneff, R., Fishman, J., Mellor, J., Earl, L., Taylor, Y., Simons, A., Conyers, J., Mulherin, B., Majerus, E., & Röth, A. (2024). Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health‐related quality of life and productivity. European Journal of Haematology. https://doi.org/10.1111/ejh.14139

Vancouver

Wilson K, Rich C, Hakimi Z, Horneff R, Fishman J, Mellor J, et al. Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health‐related quality of life and productivity. European Journal of Haematology. 2024. doi:10.1111/ejh.14139

BibTeX
@article{Wilson2024,
  author = {Wilson, Koo and Rich, Carly and Hakimi, Zalmai and Horneff, Regina and Fishman, Jesse and Mellor, Jennifer and Earl, Lucy and Taylor, Yasmin and Simons, Alice and Conyers, Joe and Mulherin, Brian and Majerus, Elaine and Röth, Alexander},
  title = {Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: Its use, its clinical effectiveness, and its influence on health‐related quality of life and productivity},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14139}
}
Kostenlos starten →